Patents Assigned to Synlogic Operating Company, Inc.
  • Bacteria engineered to treat diseases associated with hyperammonemia
    Patent number: 11060073
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating disorders associated with hyperammonemia are disclosed.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: July 13, 2021
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Vincent M Isabella, Jonathan W. Kotula, Paul F. Miller, Suman Machinani
  • Bacteria Engineered to Treat Diseases that Benefit from Reduced Gut Inflammation and/or Tighten Gut Mucosal Barrier
    Publication number: 20210095297
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
    Type: Application
    Filed: May 1, 2020
    Publication date: April 1, 2021
    Applicant: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller
  • Bacteria engineered to treat a disease or disorder
    Patent number: 10933102
    Abstract: Genetically programmed microorganisms, such as bacteria, pharmaceutical compositions thereof, and methods of modulating and treating a disease and/or disorder are disclosed.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: March 2, 2021
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Paul F. Miller, Jonathan W. Kotula, Vincent M. Isabella, Suman Machinani, Adam B. Fisher, Yves Millet
  • Bacteria engineered to reduce hyperphenylalaninemia
    Patent number: 10610546
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: April 7, 2020
    Assignee: Synlogic Operating Company Inc.
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Yves Millet, Sarah Rowe
  • MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNE MODULATORS AND ANTI-CANCER THERAPEUTICS IN TUMOR CELLS
    Publication number: 20190336544
    Abstract: Genetically programmed microorganisms, such as bacteria or virus, pharmaceutical compositions thereof, and methods of modulating and treating cancers are disclosed.
    Type: Application
    Filed: January 5, 2018
    Publication date: November 7, 2019
    Applicants: Synlogic Operating Company, Inc., Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Jonathan W. Kotula, Vincent M. Isabella, Paul F. Miller, Suman Machinani, Saurabh Saha, Adam B. Fisher, Yves Millet, Ning Li, Jose M. Lora
  • BACTERIA ENGINEERED TO TREAT METABOLIC DISEASES
    Publication number: 20190298779
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of attenuating metabolic diseases are disclosed.
    Type: Application
    Filed: June 24, 2016
    Publication date: October 3, 2019
    Applicant: Synlogic Operating Company, Inc.
    Inventors: Dean FALB, Vincent M. ISABELLA, Jonathan W. KOTULA, Paul F. MILLER, Sarah ROWE, Yves MILLET, Adam FISHER
  • Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
    Patent number: 10273489
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: April 30, 2019
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller
  • Bacteria engineered to reduce hyperphenylalaninemia
    Patent number: 10195234
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: February 5, 2019
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Sarah Rowe, Yves Millet